Mereo BioPharma Group Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Mereo BioPharma Group plc income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.007.910.0049.370.000.000.00
Cost of Revenue0.0011.94-1.1524.250.0023.6122.70
Gross Profit0.00-4.021.1525.130.00-23.61-22.70
Operating Expenses
Research & Development20.9315.4529.4731.9022.320.0022.70
Selling, General & Administrative26.4313.5026.1121.5728.9715.9111.78
Operating Expenses47.3628.9553.8453.4751.2915.9111.78
Operating Income-47.36-32.97-52.70-28.35-51.29-39.52-34.48
Other Income/Expense
Interest Income3.042.130.840.000.010.000.00
Interest Expense1.372.884.18-5.11-8.500.000.00
Other Income/Expense4.11-0.2513.1053.88-150.192.850.00
Income
Income Before Tax-43.25-34.65-42.9419.28-227.25-41.12-37.31
Income Tax Expense0.00-1.47-0.722.05-3.85-6.27-5.28
Net Income-43.25-33.18-42.2217.23-223.40-34.84-32.03
Net Income - Continuous Operations-43.25-29.47-42.2217.170.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-40.80-32.23-37.87-28.25-49.11-34.94-34.25
EBIT-45.72-33.08-38.76-28.35-51.29-36.51-34.25
Depreciation & Amortization1.091.060.890.102.180.000.00
Earnings Per Share
Basic EPS-----3.00--
Diluted EPS-----3.00--
Basic Shares Outstanding147.92659.45113.99105.5667.7989.4271.14
Diluted Shares Outstanding147.92659.45113.99111.0667.7989.4271.14